Regulatory Affairs Syndicator

Reuters - Food and Drug Administration in 2007. “Arpida aims to launch iclaprim in its first indication in the U.S. in 2008. The oral formulation is between one year and one and a half years behind the intravenous formulation,” a spokesman for the company said. …